December 11, 2024

nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines

4 months ago talkbio0Tagged Biotechnology, Chroma Medicine, epigenetic editing, financing characteristics, genetic medicines, Merger, nChroma, Non-Viral Delivery

nChroma Bio, Chroma Medicine, Nvelop Therapeutics, Genetic Medicines, Epigenetic Editing, Non-Viral Delivery, Biotechnology, Merger, Financing

Walgreens Boots Alliance in Negotiations for Potential Sale to Private Equity Firm Sycamore Partners

4 months ago talkbio0Tagged Boots Alliance, Health care facility, Industry, Partner in relationship, Platanus occidentalis whole extract, private equity sale, Walgreens

Walgreens Boots Alliance, Sycamore Partners, private equity sale, retail industry, healthcare retail

From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics

4 months ago talkbio0Tagged Acquisition, allogeneic cell therapy, biotech, CAR-T, Drug Industry, Genetic, genetic medicines, Poseida Therapeutics/ Inc., Roche (company)

Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

4 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies

Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants

4 months ago talkbio0Tagged Advisory Committees, concerns, Infant, Moderna, Respiratory syncytial virus, RNA, Messenger, Safety, United States Food and Drug Administration, Vaccines

Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

4 months ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)

Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial

4 months ago talkbio0Tagged Cardiff Oncology, first-line, onvansertib, ORR, Phase 2, RAS, RAS-mutated

Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.

uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130

4 months ago talkbio0Tagged Accelerated, AMT-130, Approved, cUHDRS, gene therapy, Huntington 's disease, NEFL gene, NfL, Regenerative Medicine, RMAT, UniQure, United States Food and Drug Administration

uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)